Post-PV MF
6 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib (NCT05280509) | Telios Pharma, Inc. | 2022-06-09 |
| KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF (NCT04640532) | Kartos Therapeutics, Inc. | 2020-11-17 |
| MPN-RC 118 AVID200 in Myelofibrosis (NCT03895112) | John Mascarenhas | 2019-02-15 |
| Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF (NCT01644110) | University of Ulm | 2013-08-01 |
Track Post-PV MF automatically
Every clearance here is in the API, with alerts when new ones post.